Quantification of circulating tumour cells over time in dogs with appendicular osteosarcoma

Vet Comp Oncol. 2023 Sep;21(3):541-550. doi: 10.1111/vco.12918. Epub 2023 Jun 19.

Abstract

Enumeration of circulating tumour cells (CTC) has shown promise for prognostication and guidance of therapeutic decisions in human cancers. The objective of this study was to enumerate CTC over time in dogs with naturally occurring osteosarcoma (OSA), and to determine correlation with patient outcome. Twenty-six dogs with OSA and no evidence of metastatic disease at the time of amputation were enrolled. Dogs were assessed for lung metastases and CTC prior to and following amputation, and at each chemotherapy visit. Twenty-one dogs completed the study. Nineteen dogs were euthanized and two were alive and free of metastases. Overall survival time ranged from 88 to 1058 days (median survival time (MST) 374 days). Increased serum alkaline phosphatase activity, advanced age, and higher body weight were significantly associated with lower MST. Dogs with OSA had a mean of 356 (0 to 4443) CTC/106 leukocytes. In 12 of 15 dogs that developed radiographic evidence of metastasis, a pre-metastatic CTC spike was retrospectively detectable on average 36.5 (1-100 days) days prior to metastasis and was associated with significantly shorter MST (301 ± 64 vs. 626 ± 55 days; p = .0107). In a multivariable analysis, dogs with a CTC spike were 10× more likely to die compared with those without. These results suggest that a spike in CTC frequency precedes detection of metastasis in dogs with OSA and is associated with shorter survival. More frequent enumeration of CTC in a larger cohort of dogs with OSA may be warranted.

Keywords: bone cancer; canine; flow cytometry; metastasis; sarcoma.

MeSH terms

  • Animals
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / veterinary
  • Dog Diseases* / pathology
  • Dogs
  • Humans
  • Neoplastic Cells, Circulating*
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / veterinary
  • Retrospective Studies